Onkure Therapeutics Inc
OKUR2.170USD
-0.030-1.37%
Market hours （ET）Quotes delayed by 15 min
29.17MMarket Cap
LossP/E TTM
More Details of Onkure Therapeutics Inc Company
OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a robust pipeline of tumor-agnostic candidates. The Company is developing OKI-219, a selective PI3KαH1047R inhibitor, as its lead program. OKI-219 is being evaluated in a Phase I clinical trial in solid tumor patients with PI3KαH1047R mutations, including breast cancer. The Company is also focused on targeting oncogenic PI3Kα and has multiple programs designed to enable targeting of this key oncogene.
Company Info
Ticker SymbolOKUR
Company nameOnkure Therapeutics Inc
IPO dateApr 09, 2021
CEODr. Nicholas A. Saccomano, Ph.D.
Number of employees46
Security typeOrdinary Share
Fiscal year-endApr 09
Address6707 Winchester Circle, Suite 400
CityBOULDER
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code80301
Phone17203072892
Websitehttps://onkuretherapeutics.com/
Ticker SymbolOKUR
IPO dateApr 09, 2021
CEODr. Nicholas A. Saccomano, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Isaac Manke, Ph.D.
Dr. Isaac Manke, Ph.D.
Independent Director
Independent Director
9.78K
+181.93%
Mr. Michael (Mike) Grey
Mr. Michael (Mike) Grey
Executive Director
Executive Director
--
--
Mr. Jason A. Leverone, CPA
Mr. Jason A. Leverone, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Nicholas A. Saccomano, Ph.D.
Dr. Nicholas A. Saccomano, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Samuel Agresta, M.D.
Dr. Samuel Agresta, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Andrew Philips, Ph.D.
Dr. Andrew Philips, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Dylan Hartley, Ph.D.
Dr. Dylan Hartley, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ed T. Mathers ,
Ed T. Mathers ,
Independent Director
Independent Director
--
--
Ms. Valerie M. Jansen, M.D., Ph.D.
Ms. Valerie M. Jansen, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. R. Michael Carruthers
Mr. R. Michael Carruthers
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Isaac Manke, Ph.D.
Dr. Isaac Manke, Ph.D.
Independent Director
Independent Director
9.78K
+181.93%
Mr. Michael (Mike) Grey
Mr. Michael (Mike) Grey
Executive Director
Executive Director
--
--
Mr. Jason A. Leverone, CPA
Mr. Jason A. Leverone, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Nicholas A. Saccomano, Ph.D.
Dr. Nicholas A. Saccomano, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Samuel Agresta, M.D.
Dr. Samuel Agresta, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Andrew Philips, Ph.D.
Dr. Andrew Philips, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Mon, Jul 28
Updated: Mon, Jul 28
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Acorn Capital Advisors, LLC
22.14%
Citadel Advisors LLC
8.33%
Perceptive Advisors LLC
7.83%
Samsara BioCapital, LLC
6.43%
Shay Capital LLC
6.32%
Other
48.95%
Shareholders
Shareholders
Proportion
Acorn Capital Advisors, LLC
22.14%
Citadel Advisors LLC
8.33%
Perceptive Advisors LLC
7.83%
Samsara BioCapital, LLC
6.43%
Shay Capital LLC
6.32%
Other
48.95%
Shareholder Types
Shareholders
Proportion
Hedge Fund
30.57%
Investment Advisor
30.02%
Venture Capital
15.38%
Private Equity
11.67%
Investment Advisor/Hedge Fund
10.55%
Individual Investor
1.66%
Research Firm
0.10%
Other
0.06%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
185
12.82M
99.94%
-1.09M
2025Q1
187
12.71M
99.28%
-1.05M
2024Q4
190
12.64M
105.50%
+4.22M
2024Q3
172
2.79M
546.32%
-1.40M
2024Q2
171
3.11M
93.03%
-1.12M
2024Q1
161
3.05M
91.28%
-864.58K
2023Q4
152
2.81M
85.98%
-309.72K
2023Q3
128
3.01M
91.00%
-83.83K
2023Q2
119
2.90M
88.58%
+621.98K
2023Q1
109
1.98M
78.98%
-170.10K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Acorn Capital Advisors, LLC
2.84M
22.14%
+1.40M
+97.24%
May 15, 2025
Citadel Advisors LLC
1.07M
8.33%
-6.21K
-0.58%
Mar 31, 2025
Perceptive Advisors LLC
1.00M
7.83%
--
--
Mar 31, 2025
Samsara BioCapital, LLC
824.15K
6.43%
--
--
Mar 31, 2025
Shay Capital LLC
810.21K
6.32%
+659.18K
+436.43%
May 15, 2025
The Vanguard Group, Inc.
706.73K
5.51%
--
--
Mar 31, 2025
Vestal Point Capital, LP
635.00K
4.95%
--
--
Mar 31, 2025
Deep Track Capital LP
523.99K
4.09%
--
--
Mar 31, 2025
StepStone Group LP
491.94K
3.84%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
478.55K
3.73%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Invesco Dorsey Wright SmallCap Momentum ETF
0%
Global X Russell 2000 ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares UltraPro Russell2000
0%
Dimensional US Core Equity 1 ETF
0%
ALPS Medical Breakthroughs ETF
0%
Proshares Ultra Russell 2000
0%
Global X Russell 2000 Covered Call ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
View more
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Invesco Nasdaq Biotechnology ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
ALPS Medical Breakthroughs ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
ProShares Ultra Nasdaq Biotechnology
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 03, 2024
Merger
10<1
Oct 03, 2024
Merger
10<1
Oct 03, 2024
Merger
10<1
Oct 03, 2024
Merger
10<1
Date
Type
Ratio
Oct 03, 2024
Merger
10<1
Oct 03, 2024
Merger
10<1
Oct 03, 2024
Merger
10<1
Oct 03, 2024
Merger
10<1
